[go: up one dir, main page]

WO2018000793A1 - Échafaudage biologique composite poreux de phosphate de calcium- sulfate de calcium contenant du magnésium/zinc dégradable - Google Patents

Échafaudage biologique composite poreux de phosphate de calcium- sulfate de calcium contenant du magnésium/zinc dégradable Download PDF

Info

Publication number
WO2018000793A1
WO2018000793A1 PCT/CN2017/000099 CN2017000099W WO2018000793A1 WO 2018000793 A1 WO2018000793 A1 WO 2018000793A1 CN 2017000099 W CN2017000099 W CN 2017000099W WO 2018000793 A1 WO2018000793 A1 WO 2018000793A1
Authority
WO
WIPO (PCT)
Prior art keywords
zinc
magnesium
source
calcium
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/000099
Other languages
English (en)
Chinese (zh)
Inventor
李亚屏
李桑
陆继业
汤亭亭
蒋国强
傅俊
毛海蛟
熊汉锋
聂磊
郑建民
张国锋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201610523497.4A external-priority patent/CN106310363B/zh
Application filed by Individual filed Critical Individual
Publication of WO2018000793A1 publication Critical patent/WO2018000793A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/01—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics
    • C04B35/447—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on phosphates, e.g. hydroxyapatite
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B38/00—Porous mortars, concrete, artificial stone or ceramic ware; Preparation thereof
    • C04B38/08—Porous mortars, concrete, artificial stone or ceramic ware; Preparation thereof by adding porous substances

Definitions

  • the invention relates to the field of medical materials, in particular to a calcium phosphate-calcium sulfate porous composite biological scaffold which can degrade magnesium and zinc.
  • Bone transplantation is a tissue transplant that is only less than blood transfusion.
  • the research and development of bone substitute materials is one of the focuses of medical research. There are researches on the mechanism of bone substitute materials and the body in China's 12th Five-Year National Project.
  • the human bones and bones have elements such as Ca, P, C, O, H, S, Fe, Mg, Cu, Si, Zn, Mn, Na, K, etc., and there are extensive homogenous replacement behaviors in human bone mineralization, human bones.
  • the ideal bone graft replacement material or bone tissue engineering scaffold material should have the following conditions: 1) good bone conductivity, material with ideal three-dimensional interpenetrating mesh structure, as high porosity and specific surface area as possible; 2) Osteoinductive; 3) good biocompatibility and surface chemistry and microstructure supporting bone cell growth and functional differentiation; 4) good biodegradability; 5) part of the material that bears bone conduction must have Sufficient mechanical strength and load carrying capacity; 6) easy to process.
  • a kind of apatite cement, ⁇ -tricalcium phosphate artificial ceramics; 2 composite materials include tetracalcium phosphate / calcium hydrogen phosphate, 62.5% ⁇ -tricalcium phosphate / 26.8% anhydrous calcium hydrogen phosphate / 8.9% calcium carbonate /1.8% hydroxyapatite, 60% hydroxyapatite/40% b-tricalcium phosphate, 73% b-tricalcium phosphate/21% calcium dihydrogen phosphate/5% magnesium hydrogen phosphate, tetracalcium phosphate/hydrogen phosphate 6 kinds of synthetic cements such as calcium/amorphous calcium phosphate, ⁇ -tricalcium phosphate/calcium carbonate/calcium dihydrogen phosphate, and the formula is 80% tricalcium phosphate/20% calcium hydrogen phosphate artificial ceramic; 3, single There are four kinds of mud or particles prepared by calcium sulphate; 4, one type of silicon-containing bioglass.
  • Apatite and calcium sulfate are currently the most common alternative materials or components for bone transplantation in clinical practice.
  • ideal bone graft replacement materials in clinical practice, mainly in the ideal three-dimensional interconnected mesh structure, great porosity and specific surface area, degradability, osteoconductivity, osteoinductivity and mechanical strength. It.
  • the artificial bones with ideal three-dimensional interconnected mesh microstructures have been transformed from animal materials: two of them are porous hydroxyapatite ceramic bones prepared from high temperature sintering process of bovine cancellous bone.
  • the three-dimensional interpenetrating micro-structure of bovine cancellous bone natural bone ore is close to human bone mineral composition, with good biocompatibility, good bone conductivity and good compressive strength, free of high temperature sintering procedures. Xenogeneic bone immune rejection and pathogen introduction are possible and easy to process.
  • the porous hydroxyapatite from bovine bone has a good porosity of 60-90% and is rich in bovine bone resources, and has a pore diameter of 390-1360 ⁇ m, a bone graft replacement material slightly larger than 150-400 ⁇ m and an ideal pore diameter of the bone tissue engineering scaffold; It has good compressive strength of 1-20MPa; implanted in the body is beneficial to bone repair cell recruitment, blood vessel entry, oxygen and tissue fluid exchange, providing good physiological activity space and adhesion support for bone repair cells; its huge disadvantages
  • the bone mineral-hydroxyapatite obtained by high-temperature sintering of bovine cancellous bone is too stable, and the degradation in the body is too slow and long.
  • the solubility in calcium-phosphorus bone grafting material is the lowest, and the degradation rate is far from matching with the formation speed of new bone. , can not continue to release Higher concentrations of calcium and other osteogenesis beneficial ions, and therefore lack of good osteogenic activity, is not conducive to bone repair and transformation.
  • the ideal degradation rate is another important requirement for artificial bone or bone tissue engineering scaffolds.
  • the ideal artificial bone degradation rate should match the formation speed of new bones, and further provide space for guiding new bone formation while gradually degrading into new bone substitutes.
  • the osteogenesis beneficial ions such as calcium ions continuously released during the degradation process provide mineral recombination components for the redeposition, transformation and metabolism of bone minerals, which may stimulate the formation of new bones and have some degree of potential osteoinductivity; artificial bone Or the degradation rate of bone tissue engineering material is too fast to provide sufficient space-time support and guidance for the bone repair process, and too slow degradation will hinder the formation, replacement and shaping of new bone.
  • the degradation of inorganic bone graft materials in vivo mainly through two pathways: humoral-mediated dissolution and cell-mediated degradation.
  • the process of dissolution is the process of hydrolysis of materials and binders under the action of body fluids, and the material gradually dissociates into physical dissolution processes of particles, molecules and ions.
  • the cell-mediated degradation process is mainly the biodegradation process of phagocytosis of macrophages and osteoclasts.
  • the degradation process of inorganic bone grafting materials in vitro is related to its composition.
  • the degradation rate is closely related to the particle size, porosity, specific surface area, crystallinity and solubility of the material. Solubility is the most important factor.
  • calcium sulfate has the fastest degradation rate [calcium sulfate completely degraded in the body for 45-72d, more than twice as fast as autologous bone], hydroxyapatite in calcium phosphate material Has the slowest degradation rate [non-porous massive hydroxyapatite can not be completely degraded in the body for 10 years], far greater than the rate of new bone formation, other calcium and phosphorus components such as tricalcium phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate
  • the degradation rate of polyhydrogen phosphate, calcium pyrophosphate, etc. is in between, and has a relatively moderate degradation rate.
  • Calcium sulphate forms a high calcium environment when it degrades in vivo, providing a calcium source for bone formation of new bone tissue, and binding to phosphate in body fluids to promote new bone minerals.
  • the potential osteoinductive activity is related to the local high calcium and acidity microenvironment during the dissolution of calcium sulfate; the degradation of calcium sulfate in the body forms a calcium source for the formation of new bone during localized high calcium environment, and promotes it to varying degrees.
  • Osteoblast formation and differentiation the degradation of calcium sulfate in the body to form a local acid micro-environment may promote the micro-dissolution of human bone minerals, resulting in osteogenic active protein exposure, which is conducive to the formation of new bone; but the clinical application of calcium sulfate mud paste Or the common disadvantage of the same synthetic material is that it is difficult to have the ideal three-dimensional interconnected mesh structure, and the complete degradation time of calcium sulfate in the body is 45-72d, which is more than twice as fast as the autogenous bone. It is difficult to make the new bone formation continuous and stable.
  • Bone conduction support can not provide three-dimensional porous micro-structure for bone tissue regeneration, that is, lack of good osteoconductive structural basis repair cells, blood vessels In the graft, it is not conducive to the formation of new bones; even if the calcium sulfate elemental scaffold with high porosity and high specific surface area of three-dimensional interconnected mesh structure is successfully prepared, the degradation rate will be faster and the strength will be worse; the calcium sulfate material dissolves. After the drop, the local microenvironment may be acidified and may cause an inflammatory reaction.
  • the advantage of synthetic composite materials is that the composition of different degradation characteristics and the composition ratio of the components can be selected to achieve a certain balance between the degradation rate and pH of the composite material, and it is possible to adsorb more active proteins (signal proteins) in the human body. Improve the biological activity of materials and more meet the ideal requirements for bone graft replacement materials.
  • the biological activity of calcium phosphate and other bio-based materials may be enhanced by the incorporation of biologically active ions.
  • biologically active ions can effectively stimulate protein activity and promote fine Cell growth and bone growth.
  • the human body contains about 25 g of magnesium, which plays an important role in human bone formation and all growth processes, maintenance of bone cell structure and function, bone metabolism and remodeling.
  • Calcium magnesium phosphate-based bone cement with low magnesium content can significantly improve cell adhesion.
  • Calcium-doped calcium phosphate cement has become an increasingly important new bone repair biomaterial because it can promote the interface between implant materials and bone tissue: magnesium-doped bone cement is easier to prepare, and 73% b-tricalcium phosphate in western countries such as New Zealand.
  • the bone cement of /21% calcium dihydrogen phosphate / 5% magnesium hydrogen phosphate formula is clinically applied.
  • the composite formula contains magnesium bone cement with degradability, which can release beneficial elements such as calcium, phosphorus and magnesium. It can be degraded and ion exchanged in the body after transplantation, and does not have three-dimensional interpenetrating mesh structure to hinder repair of cells and blood vessels. Early in-depth grafts, lacking good three-dimensional interconnected mesh structure of bone conduction.
  • the porous scaffold transforms the elemental hydroxyapatite porous scaffold into a composite porous bioscaffold containing calcium and zinc containing calcium and zinc with good degradation characteristics.
  • the object of the present invention is to solve the problems that the existing bone graft substitute materials have good three-dimensional interpenetrating mesh structure, mechanical strength, degradability and biological activity, and the sulfur, phosphorus, magnesium and zinc are simultaneously incorporated into the natural bone mineral complex.
  • the calcined bovine cancellous elemental porous hydroxyapatite can be transformed into the doped bone active ion magnesium and zinc.
  • Calcium phosphate-calcium sulfate composite scaffold material the magnesium-calcium-containing calcium phosphate-calcium sulfate porous composite biological scaffold of the invention has good three-dimensional interpenetrating mesh structure and osteoconductivity, degradability, good mechanical strength and biological Compatibility; at the same time, the growth of calcium sulfate whiskers with larger aspect ratio in the mesh can increase the specific surface area of the material and may improve cell adhesion.
  • the composite bioscaffold may have potential osteoinductivity due to the effective incorporation of the osteogenic active ion magnesium, zinc and calcium sulfate which can produce a local high calcium environment upon degradation.
  • the composite bioscaffold may more satisfy the ideal conditions for bone graft replacement materials or bone tissue engineering scaffold materials.
  • a calcium phosphate-calcium sulfate porous composite biological scaffold capable of degrading magnesium and zinc, and removing the porous scaffold of bovine calcined cancellous bone and bone through a quaternary system containing magnesium source, zinc source, sulfur source and phosphorus source After drying, it is obtained by calcination at a high temperature.
  • X-ray powder diffraction analysis of the composite bioscaffold material is a calcium phosphate-calcium sulfate porous composite bioscaffold material containing active ions of magnesium and zinc, such as calcium sulfate / zinc pyrophosphate / magnesium zinc phosphate, calcium sulfate / zinc pyrophosphate / magnesium magnesium phosphate / Hydroxyapatite, calcium sulfate / zinc phosphate / magnesium magnesium phosphate, calcium sulfate / magnesium zinc phosphate / magnesium pyrophosphate.
  • active ions of magnesium and zinc such as calcium sulfate / zinc pyrophosphate / magnesium zinc phosphate, calcium sulfate / zinc pyrophosphate / magnesium magnesium phosphate / Hydroxyapatite, calcium sulfate / zinc phosphate / magnesium magnesium phosphate, calcium sulfate / magnesium zinc phosphate / magnesium pyrophosphate.
  • the composite stent contains magnesium and zinc apatite components with good degradation rate, such as tricalcium phosphate, magnesium pyrophosphate, magnesium zinc phosphate, zinc pyrophosphate, tri-zinc phosphate, etc., which have a fast absorption rate and complete bioabsorption.
  • the potential osteogenic calcium sulphate and some materials also contain the slowest rate of dissolution of hydroxyapatite in the phosphorus compound; due to the obvious difference in the rate of dissolution between the various components of the composite bioscaffold material, the composite bioscaffold material can be realized Gradient degradation; because we change the composition ratio and mass ratio of the composite bioscaffold material by changing the mass ratio of the reactants in the compound formula, concentration, impregnation and hydrothermal reaction time, calcination temperature and time, the composite bioscaffold material The degradation rate can thus be effectively controlled, such as in the case of other conditions within the experimental conditions, with the solution
  • the increase of sulfur content can gradually increase the content of calcium sulfate; with the increase of phosphorus in the unit solution, the hydroxyapatite with a ratio of calcium to phosphorus of 1.67 gradually becomes zinc phosphorus, (calcium + magnesium) phosphorus, (zinc).
  • the composite bioscaffold material can form a high calcium environment favorable for new bone formation in the early stage of simulated body fluid environment, and has sustained release of calcium, magnesium and zinc ions, which may support the potential osteogenic activity of the composite bioscaffold material.
  • the composite biological scaffold material retains the extraordinar three-dimensional interconnected mesh microstructure of the bovine natural bone mineral and its good mechanical strength, and at the same time, whisker growth with a large aspect ratio in the growth of the mesh can increase the material ratio.
  • Surface area improves cell and protein adhesion.
  • bone repair cells were observed to adhere, proliferate, differentiate, and secrete bone matrix in the scaffold.
  • Very early blood vessel formation was observed in the scaffold, and the osteogenesis process was similar to the physiological state of intramembranous osteogenesis; No obvious immunological rejection and inflammatory reaction were observed during the observation period, suggesting that the composite bioscaffold material has good biocompatibility.
  • the rapid and good bone repair in the animal bone defect area also suggests the potential osteogenic activity of the composite bioscaffold material. .
  • the quaternary system for treating the bovine calcined cancellous bone ore porous scaffold containing magnesium source, zinc source, sulfur source and phosphorus source is selected as one of the following schemes:
  • the hydrothermal reaction is carried out by a constant temperature hydrothermal method, and the temperature is controlled at 60-70 ° C for 36-72 hours.
  • the ratio of the liquid of the bovine calcined cancellous bone ore porous stent to the magnesium source-zinc source composite solution is 10g: 40-60mL, and the bovine calcined cancellous bone and bone porous support and the sulfur source-phosphorus source
  • the solid solution ratio of the composite solution was 10 g: 50-100 mL.
  • the ratio of the liquid of the bovine calcined cancellous bone mineral porous scaffold to the magnesium source-zinc source-sulfur source-phosphorus source complex solution is 10 g: 50-100 mL.
  • the high temperature calcination parameter is calcined at 750-900 ° C for 2-9 hours.
  • the magnesium source is magnesium sulfate; the zinc source is zinc nitrate; the sulfur source is a combination of sulfuric acid and soluble sulfate, the soluble sulfate is magnesium sulfate or a combination of magnesium sulfate and sodium sulfate;
  • the phosphorus source is a combination of phosphoric acid or phosphoric acid and diammonium hydrogen phosphate.
  • Magnesium sulphate in the magnesium source is both a source of magnesium ions and a source of sulfur.
  • the final concentration of magnesium ions in the quaternary system containing the magnesium source, the zinc source, the sulfur source and the phosphorus source is 0.05-0.2 mol/L, and the final concentration of zinc ions is 0.2-0.8 mol/L.
  • the final concentration of the sulfuric acid in the quaternary system containing the magnesium source, the zinc source, the sulfur source and the phosphorus source is 0.1-0.2 mol/L, and the final concentration of the sulfate provided by the sulfate is 0.05-0.2 mol/L.
  • the final concentration of phosphoric acid is 1.7-3.4 wt%, and the final phosphorus concentration provided by diammonium hydrogen phosphate is 0.1-0.8 mol/L.
  • Sulfate contains all of the sulfates in the magnesium source and sulfur source.
  • the calcium phosphate-zinc calcium phosphate-calcium porous composite bioscaffold has a material composition of one of the following composite components: calcium sulfate/zinc pyrophosphate/magnesium magnesium phosphate, calcium sulfate/zinc pyrophosphate / Magnesium calcium phosphate / hydroxyapatite, calcium sulfate / zinc phosphate / magnesium magnesium phosphate, calcium sulfate / magnesium zinc phosphate / magnesium pyrophosphate.
  • the magnesium phosphate-calcium phosphate porous composite bioscaffold demagnetizes the molar percentage of magnesium ions to total cations in the range of 1-15%, and the molar percentage of zinc ions to the total cations is 10-85%.
  • the bovine calcined cancellous bone mineral porous scaffold has a porosity of 70-85% and a pore diameter of 400-1400 ⁇ m.
  • the calcium phosphate-zinc calcium phosphate-calcium sulfate porous composite bioscaffold can be degraded by a gradient; the degradable calcium phosphate-calcium phosphate porous composite bioscaffold retains the calcined pine
  • the three-dimensional interconnected mesh structure and mechanical strength of the porous bone ore bone support, and the whisker growth with large aspect ratio in the mesh, the whisker aspect ratio is 8-25:1, which can effectively increase the specific surface area of the material. .
  • the preparation method of the bovine calcined cancellous bone ore porous scaffold is:
  • the raw material bone treated in the step (2) is dried in a constant temperature oven at 80-120 ° C for 12-24 hours, then placed in a calcining furnace, calcined at 900-1200 ° C for 8-12 hours, and cooled to obtain a calcined pine. Porous bone mineral bone support.
  • the invention can stably and effectively convert the calcined cancellous porous hydroxyapatite elemental scaffold (bovine calcined cancellous bone and bone mineral porous scaffold) into a degradable magnesium-calcium-calcium phosphate-calcium sulfate composite scaffold material which is rich in conversion components.
  • a degradable magnesium-calcium-calcium phosphate-calcium sulfate composite scaffold material which is rich in conversion components.
  • the invention effectively incorporates osteogenic active ion magnesium ions, zinc ions, sulfate ions, phosphorus ions, etc.; magnesium-containing components are tricalcium phosphate, magnesium magnesium phosphate, magnesium pyrophosphate, and magnesium-containing components having good degradation characteristics.
  • Material The total mass of the material is 9.5-80%, the molar ratio of magnesium ion content to total cation is 1.0-15%; the zinc-containing component is magnesium zinc phosphate, zinc pyrophosphate, tri-zinc phosphate, etc.
  • the composite scaffold contains calcium sulfate, sulfuric acid which has a faster degradation rate, can be completely degraded and has potential osteoinductive active ions. Calcium accounts for 12-60% of the total mass of the composite; some composite scaffolds also contain hydroxyapatite.
  • the composite bio-scaffold material maintains the three-dimensional interpenetrating micro-structure of natural bone and bone and its good mechanical strength. At the same time, there is a bundle of larger aspect ratio whiskers in the mesh, and the whisker aspect ratio is 8-25. : 1, can effectively increase the specific surface area of the material to improve cell adhesion. Due to the large difference in the dissolution rate of the components, the composite bioscaffold material can achieve stepwise dissolution; and the composition and mass ratio of the composite bioscaffold material can be effectively regulated according to the formulation and the production process, as in the experiment.
  • the content of calcium sulfate can be gradually increased with the increase of sulfur in the solution; with the increase of phosphorus in the unit solution, the hydroxyapatite with a ratio of calcium to phosphorus of 1.67
  • Zinc pyrophosphate, magnesium pyrophosphate which has a ratio of zinc, (calcium + magnesium), (zinc + magnesium) to phosphorus of 1.5, magnesium triphosphate, zinc phosphate, zinc triphosphate, zinc phosphate, magnesium phosphate Transformation, we can effectively regulate the composition and mass ratio of the scaffold components, so the dissolution rate of the composite bioscaffold material can be effectively regulated.
  • Calcium sulfate degradation can form an early high calcium environment, containing magnesium, zinc degradable calcium phosphate such as magnesium tricalcium phosphate, magnesium zinc phosphate, zinc triphosphate and zinc pyrophosphate, magnesium pyrophosphate degradation sustainable release of osteogenic active ion magnesium , zinc and calcium ions, etc., are conducive to the formation of new bone and provide further space for bone repair; the material can maintain good mechanical strength and mesh structure after a large proportion of dissolution, these can be simulated in the body fluid dissolution test. It was confirmed that the dissolution and redeposition of the magnesium-containing, zinc-calcium phosphate-calcium sulfate composite scaffold can be seen under electron microscope.
  • the calcined bovine cancellous bone mineral of the invention transforms the magnesium-containing, zinc-calcium phosphate-calcium sulfate composite scaffold material into the cancellous bone defect region of the animal, and the repaired cells can be well recruited, adhered, proliferated and differentiated, secreted matrix and rapidly The formation of vascular network, the material can achieve intra-membranous osteogenesis similar to physiological state, suggesting good bone conduction and potential osteoinductive activity of calcined bovine cancellous bone minerals transformed with magnesium-doped, calcium-calcium phosphate-calcium sulfate composite scaffold; No immunological rejection and obvious inflammation were found during the process, suggesting that the calcined bovine cancellous bone mineral was transformed into a magnesium-calcium-calcium-calcium phosphate-calcium sulfate composite scaffold with good biocompatibility.
  • the calcined bovine cancellous bone mineral is transformed into a calcium phosphate-zinc calcium phosphate-calcium sulfate porous composite scaffold material which has good three-dimensional interconnected mesh structure and osteoconductivity, degradability, good mechanical strength and biocompatibility.
  • the composite bioscaffold material may have potential osteoinductivity due to the effective incorporation of the osteogenic active ion magnesium, zinc and calcium sulfate which can produce a local high calcium environment upon degradation.
  • the composite bioscaffold may more satisfy the ideal conditions for bone graft replacement materials or bone tissue engineering scaffold materials.
  • Figure 1 is a diagram showing the XRD analysis of a component of the product of the present invention.
  • Figure 2 is a scanning electron micrograph of one of the products of the present invention.
  • Figure 4 is a scanning electron micrograph of a material after simulating a body fluid dissolution test of the product of the present invention.
  • Figure 5 is an early histological illustration of a transplantation experiment of the product of the present invention.
  • Figure 6 is an early histological illustration of another transplantation experiment of the product of the present invention.
  • Figure 7 is a histological illustration of a later stage of a transplant experiment of the product of the present invention.
  • bovine cancellous bone bovine femoral condyle cancellous bone
  • the raw material bone treated in the step (2) is dried in a constant temperature oven at 100 ° C for 18 hours, then placed in a calcining furnace, calcined at 1000 ° C (heating rate 10 ° C / min) for 10 hours, and then calcined with the furnace.
  • Calcined cancellous bone ore porous stent is
  • the final concentration of magnesium ions in the quaternary system containing the magnesium source, the zinc source, the sulfur source and the phosphorus source is 0.05-0.2 mol/L, and the final concentration of zinc ions is 0.2-0.8 mol/L;
  • the concentration is 0.1-0.15mol/L
  • the final concentration of sulfate provided by sulfate is 0.05-0.3mol/L
  • the final concentration of phosphoric acid is 1.7-3.4wt%
  • the final concentration of phosphorus provided by diammonium hydrogen phosphate is 0.1-0.8.
  • Mol/L for ingredients are 0.1-0.15mol/L, the final concentration of sulfate provided by sulfate is 0.05-0.3mol/L, the final concentration of phosphoric acid is 1.7-3.4wt%, and the final concentration of phosphorus provided by diammonium hydrogen phosphate is 0.1-0.8.
  • Mol/L for ingredients.
  • step E The bovine calcined cancellous bone ore porous support after the treatment in step D is placed in a calciner, calcined at 750-900 ° C (heating rate 2.5 ° C / min) for 2-9 hours, and calcined pine after cooling with the furnace. Porous bone mineral porous scaffold conversion material.
  • the final concentration of magnesium ions in the quaternary system containing the magnesium source, the zinc source, the sulfur source and the phosphorus source is 0.05-0.2 mol/L, and the final concentration of zinc ions is 0.2-0.8 mol/L;
  • the concentration is 0.1-0.15 mol/L
  • the final concentration of sulfate provided by sulfate is 0.05-0.3 mol/L
  • the final concentration of phosphoric acid is 1.7-3.4 wt%.
  • the final concentration of phosphorus provided by diammonium hydrogen phosphate is 0.1-0.8 mol/L.
  • XRD X-ray diffraction
  • part of the sample was selected for observation by microscopy with scanning electron microscopy; animal experiments for simulating body fluid dissolution and bone defect repair were performed.
  • the general shape and strength of the material were observed generally, and some samples were tested for compressive strength using INSTRON-5566.
  • the simulated body fluid elution experiment uses medical sodium chloride injection as a simulated body fluid, and the solid-liquid mass ratio of the test material to the simulated body fluid is 1 gram: 100 ml, placed in a covered beaker, and simulated body fluid is carried out under the constant temperature of 37 ° C.
  • the AU5800 automatic biochemical analyzer was used to measure the calcium, phosphorus and magnesium ions in the simulated body fluid every 3 days.
  • the simulated body fluid was replaced 40% every 3 days before the dissolution.
  • the simulated body fluid was not replaced in the later stage; the mass of the sample after 30 days of the dissolution test was measured by a domestic electronic balance and the degradation rate was calculated; XRD analysis and scanning electron microscope observation of the material before and after the start of the dissolution test were performed.
  • Animal bone defect repair test selected 48 healthy New Zealand white rabbits, which resulted in bone defects of 8 mm in diameter in rabbit femoral condyles.
  • mice were randomly divided into experimental group (porous composite biomaterial) and control group (imported synthetic calcium phosphate material).
  • the same artificial bone defects were made to the experimental group and the control group, respectively, and then the rabbits in the experimental group were treated with porous composite organisms. The bone defect was repaired by the material.
  • the rabbits in the control group were treated with imported synthetic calcium phosphate bone substitute material for bone defect repair.
  • the experimental animals were sacrificed at 1, 2, 4 and 8 weeks after operation to perform histological examination of bone defect repair.
  • magnesium sulfate hexahydrate According to the amount of 0.2 mol/L magnesium sulfate hexahydrate, 0.4 mol/L zinc nitrate hexahydrate, 3.4 wt% phosphoric acid, 0.1 mol/L sulfuric acid, 0.4 mol/L diammonium hydrogen phosphate, 2.4 g of magnesium sulfate hexahydrate, Liushui 5.9 g of zinc nitrate, 2 ml of phosphoric acid (85 wt%), 5 ml of sulfuric acid, and 2.64 g of diammonium hydrogen phosphate.
  • Hydrogen diammonium 2.64 g was prepared into 50 ml of phosphorus and sulfur composite solution, and the bovine calcined cancellous bone and bone porous support was put into the 70 ° C reaction for 60 hours, and taken out and dried at 70 ° C for 48 hours; the temperature was raised from 2.5 ° C to 750 ° C per minute to maintain After 2 hours, the furnace was cooled to room temperature to obtain 604153A;
  • magnesium sulfate hexahydrate 0.6 mol/L zinc nitrate hexahydrate, 1.7 wt% phosphoric acid, 0.1 mol/L sulfuric acid, 0.4 mol/L diammonium hydrogen phosphate, 1.2 g of magnesium sulfate hexahydrate, Liushui 8.93 g of zinc nitrate, 1 ml of phosphoric acid, 5 ml of sulfuric acid, and 2.64 g of diammonium hydrogen phosphate.
  • magnesium sulfate hexahydrate Liushui, in an amount of 0.1 mol/L magnesium sulfate hexahydrate, 0.5 mol/L zinc nitrate hexahydrate, 1.7 wt% phosphoric acid, 0.1 mol/L sulfuric acid, 0.4 mol/L diammonium hydrogen phosphate. 6.94 g of zinc nitrate, 1 ml of phosphoric acid, 5 ml of sulfuric acid, and 2.64 g of diammonium hydrogen phosphate.
  • magnesium sulfate hexahydrate According to the amount of 0.05 mol/L magnesium sulfate hexahydrate, 0.6 mol/L zinc nitrate hexahydrate, 1.7 wt% phosphoric acid, 0.1 mol/L sulfuric acid, 0.6 mol/L diammonium hydrogen phosphate, 0.6 g of magnesium sulfate hexahydrate, Liushui 8.93 g of zinc nitrate, 1 ml of phosphoric acid, 5 ml of sulfuric acid, and 3.96 g of diammonium hydrogen phosphate.
  • magnesium sulfate hexahydrate According to the amount of 0.05 mol/L magnesium sulfate hexahydrate, 0.8 mol/L zinc nitrate hexahydrate, 1.7 wt% phosphoric acid, 0.1 mol/L sulfuric acid, 0.8 mol/L diammonium hydrogen phosphate, 0.6 g of magnesium sulfate hexahydrate, Liushui 8.93 g of zinc nitrate, 1 ml of phosphoric acid, 5 ml of sulfuric acid, and 5.28 g of diammonium hydrogen phosphate.
  • magnesium sulfate hexahydrate According to 0.05 mol/L magnesium sulfate hexahydrate, 0.2 mol/L zinc nitrate, 1.7 w% phosphoric acid, 0.15 mol/L sulfuric acid, 0.6 g of magnesium sulfate hexahydrate, 2.97 g of zinc nitrate hexahydrate, 1 ml of phosphoric acid, 5 ml of sulfuric acid .
  • magnesium sulfate hexahydrate According to 0.05 mol/L magnesium sulfate hexahydrate, 0.3 mol/L zinc nitrate, 1.7 wt% phosphoric acid, 0.1 mol/L sulfuric acid, 0.6 g of magnesium sulfate hexahydrate, 4.46 g of zinc nitrate, 1 ml of phosphoric acid, and 5 ml of sulfuric acid were taken.
  • magnesium sulfate hexahydrate According to 0.05 mol/L magnesium sulfate hexahydrate, 0.2 mol/L zinc nitrate, 2.55 wt% phosphoric acid, 0.1 mol/L sulfuric acid, 0.4 diammonium phosphate, 0.6 g of magnesium sulfate hexahydrate, 2.97 g of zinc nitrate, 1.5 ml of phosphoric acid. 5 ml of sulfuric acid and 2.64 g of diammonium hydrogen phosphate.
  • Calcium porous composite bioscaffold materials such as calcium sulfate / zinc pyrophosphate / magnesium zinc phosphate, calcium sulfate / zinc pyrophosphate / magnesium magnesium phosphate / hydroxyapatite, calcium sulfate / zinc phosphate / magnesium magnesium phosphate, calcium sulfate / magnesium zinc phosphate
  • a composite such as /magnesium pyrophosphate is shown in Fig. 1.
  • the magnesium-containing component is tricalcium phosphate, magnesium magnesium phosphate, magnesium pyrophosphate, etc., and the magnesium component accounts for 9.5-80% of the total mass of the material, and the molar ratio of magnesium ion content to total cation is 1.0-15.
  • the zinc-containing component is magnesium zinc phosphate, zinc pyrophosphate, tri-zinc phosphate, etc. having good degradation characteristics, the zinc-containing component accounts for 10-88% of the total mass of the material, and the molar ratio of zinc ion content to total cation is 10 -85:100; composite scaffold contains calcium sulfate with faster degradation rate, complete degradation and potential osteoinductive active ions, calcium sulfate accounts for 12-60% of the total mass of the composite; some composite scaffolds also contain hydroxyapatite .
  • the simulated body fluid elution experiment was carried out by using medical sodium chloride injection as a simulated body fluid.
  • the solid-liquid mass ratio of the test material to the simulated body fluid was 1-2 g: 100 ml, placed in a covered beaker, and simulated at 37 ° C under constant temperature.
  • the body fluid dissolution test was carried out for 4 weeks.
  • the AU5800 automatic biochemical analyzer was used to measure the calcium, phosphorus and magnesium ions in the simulated body fluid.
  • the mass of the material was measured by the domestic electronic balance for 4 weeks and the degradation rate was calculated. XRD analysis and scanning electron microscopy of the material before and at the end of the experiment. The experiment found that the material has a good degradation rate (Table 2).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Organic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Un échafaudage biologique composite poreux en phosphate de calcium- sulfate de calcium contenant du magnésium/zinc dégradable qui est préparé par: à traiter un échafaudage poreux minéral d'os spongieux calciné bovin en utilisant un système quaternaire contenant une source de magnésium/source de zinc/source de soufre/source de phosphore, à sortir le produit, de faire sécher et effectuer une calcination à haute température. L'échafaudage biologique composite poreux de phosphate de calcium-sulfate de calcium contenant du magnésium/zinc possède une structure favorable maillée d'intercommunication tridimensionnelle, et possède une bonne ostéoconductivité, une bonne dégradabilité, une bonne résistance mécanique et une bonne biocompatibilité. Les barbes de sulfate de Calcium ayant un rapport longueur/diamètre élevé croître dans les mailles, ce qui augmente la surface spécifique du matériau, et donc améliorer l'adhésion cellulaire.
PCT/CN2017/000099 2016-06-29 2017-01-04 Échafaudage biologique composite poreux de phosphate de calcium- sulfate de calcium contenant du magnésium/zinc dégradable Ceased WO2018000793A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610523497.4 2016-06-29
CN201610523497.4A CN106310363B (zh) 2015-07-01 2016-06-29 一种可降解含镁和锌的磷酸钙-硫酸钙多孔复合生物支架

Publications (1)

Publication Number Publication Date
WO2018000793A1 true WO2018000793A1 (fr) 2018-01-04

Family

ID=60788019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/000099 Ceased WO2018000793A1 (fr) 2016-06-29 2017-01-04 Échafaudage biologique composite poreux de phosphate de calcium- sulfate de calcium contenant du magnésium/zinc dégradable

Country Status (1)

Country Link
WO (1) WO2018000793A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114455834A (zh) * 2022-01-17 2022-05-10 华南理工大学 一种高强度生物活性玻璃支架及其3d打印方法
US20220193181A1 (en) * 2020-12-21 2022-06-23 Musc Foundation For Research Development S-nitrosoglutathione (gsno) and gsno reducatase inhibitors for use in therapy
CN115591027A (zh) * 2022-11-14 2023-01-13 中鼎凯瑞科技成都有限公司（Cn） 共聚体材料及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340648B1 (en) * 1999-04-13 2002-01-22 Toshiba Ceramics Co., Ltd. Calcium phosphate porous sintered body and production thereof
CN1511595A (zh) * 2002-12-31 2004-07-14 华中科技大学同济医学院附属协和医院 骨组织填充材料
CN103961742A (zh) * 2014-05-14 2014-08-06 常州大学 含有益离子的磷酸钙多孔支架的制备方法
CN105107023A (zh) * 2015-07-01 2015-12-02 李亚屏 一种骨移植用可降解多孔复合支架材料

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340648B1 (en) * 1999-04-13 2002-01-22 Toshiba Ceramics Co., Ltd. Calcium phosphate porous sintered body and production thereof
CN1511595A (zh) * 2002-12-31 2004-07-14 华中科技大学同济医学院附属协和医院 骨组织填充材料
CN103961742A (zh) * 2014-05-14 2014-08-06 常州大学 含有益离子的磷酸钙多孔支架的制备方法
CN105107023A (zh) * 2015-07-01 2015-12-02 李亚屏 一种骨移植用可降解多孔复合支架材料
CN105582574A (zh) * 2015-07-01 2016-05-18 李亚屏 一种含镁复相多孔生物陶瓷
CN105597158A (zh) * 2015-07-01 2016-05-25 李亚屏 一种骨移植用可降解多孔复合支架材料

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220193181A1 (en) * 2020-12-21 2022-06-23 Musc Foundation For Research Development S-nitrosoglutathione (gsno) and gsno reducatase inhibitors for use in therapy
CN114455834A (zh) * 2022-01-17 2022-05-10 华南理工大学 一种高强度生物活性玻璃支架及其3d打印方法
CN115591027A (zh) * 2022-11-14 2023-01-13 中鼎凯瑞科技成都有限公司（Cn） 共聚体材料及其应用
CN115591027B (zh) * 2022-11-14 2023-07-28 中鼎凯瑞科技成都有限公司 共聚体材料及其应用

Similar Documents

Publication Publication Date Title
US10828396B2 (en) Degradable magnesium-containing calcium phosphate-calcium sulfate porous composite biological scaffold
Bellucci et al. A new hydroxyapatite-based biocomposite for bone replacement
Dorozhkin Medical application of calcium orthophosphate bioceramics
US9066995B2 (en) Bone substitute material
CN102764450B (zh) 墨鱼骨转化系列多孔复相生物陶瓷及其制备方法、应用
US8734524B2 (en) Bone substitute material
Sayed et al. Effect of the injectable alginate/nano-hydroxyapatite and the silica/nano-hydroxyapatite composites on the stem cells: a comparative study
KR102230625B1 (ko) 골 대체 물질
CN104771782A (zh) 一种骨修复用材料β-磷酸三钙及其制备方法
WO2018000793A1 (fr) Échafaudage biologique composite poreux de phosphate de calcium- sulfate de calcium contenant du magnésium/zinc dégradable
JPS6040298B2 (ja) 骨欠損部及び空隙部充てん材
Zhang et al. Systematic evaluation of the osteogenic capacity of low-melting bioactive glass-reinforced 45S5 Bioglass porous scaffolds in rabbit femoral defects
WO2018000794A1 (fr) Support biologique composite poreux et dégradable à base d'apatite-sulfate contenant du magnésium/strontium
Sarkar Research Progress on Biodegradable Magnesium Phosphate Ceramics in Orthopaedic Application
CN110201228A (zh) 一种含脱钙骨基质的磷酸钙骨水泥及其制备方法和应用
WO2025145475A1 (fr) Échafaudage bio-minéralisé modifié incorporant du lithium, du magnésium et du phosphore comme base
US20250222170A1 (en) Modified biological bone mineral scaffold doped based on lithium magnesium phosphate
CN117427210A (zh) 一种植酸钙类骨替代物及其制备方法和应用
HK40013475B (en) Bone substitute material
HK40013475A (en) Bone substitute material
LE THI Substituted Apatite/poly-epsilon-caprolactone Biocomposite as Substrates and Coating on Alpha-tricalcium Phosphate Foams

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17818794

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17818794

Country of ref document: EP

Kind code of ref document: A1